ELSEVIER

Blood 142 (2023) 658–660

The 65th ASH Annual Meeting Abstracts

# ORAL ABSTRACTS

## 732.ALLOGENEIC TRANSPLANTATION: DISEASE RESPONSE AND COMPARATIVE TREATMENT STUDIES

### The Impact of *DNMT3A* Mutation on Survival of AML Patients Receiving Allogeneic Hematopoietic Cell Transplantation in First Remission Depends on the Karyotype and Co-Occurring Mutations: On Behalf of the EBMT Acute Leukemia Working Party

*Iman Abou Dalle, MD*[1], *Jacques-Emmanuel Galimard*[2,3], *Xavier Poire, MD*[4], *Anne Huynh, MD*[5], *Eva Wagner Drouet, MD*[6], *David Burns, MD PhD*[7], *Jiří Mayer, MD*[8], *Nicolaus Kröger, MD*[9], *Matthias Eder*[10], *Jaime Sanz, MD PhD*[11], *Depei Wu*[12], *Matthias Stelljes, MD*[13], *Mahmoud Aljurf, MD*[14], *Arnon Nagler, MD*[15], *Jordi Esteve, MD PhD*[16], *Fabio Ciceri*[17], *Ali Bazarbachi, MD PhD*[18], *Mohamad Mohty, MDPhD*[19,20]

[1] Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut medical center, Beirut, Lebanon
[2] Statistic and Statistic and Epidemiologic Research Center Sorbonne Paris Cit, Paris, FRA
[3] EBMT ALWP Statistical Unit, Saint Antoine Hospital, Sorbonne University, Paris, Paris, France
[4] Section of hematology, Institut Roi Albert II, Cliniques Universitaires St-Luc, Brussels, Belgium
[5] Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
[6] University Medicine Mainz, Mainz, Germany
[7] University Hospital Birmingham NHS Trust, Stoke, United Kingdom
[8] Masaryk University and University Hospital Brno, Brno, Czech Republic
[9] University Medical Center Hamburg, Hamburg, Germany
[10] Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
[11] Hematology Department, University Hospital La Fe, VALENCIA, Spain
[12] The First Affiliated Hospital of Soochow University, Suzhou, China
[13] University of Muenster, Muenster, Germany
[14] Dept of Hematology, Stem Cell Transplantation and Cellular Therapy, KFSHRC, Riyadh, Saudi Arabia
[15] Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
[16] Hematopoietic Cell Transplantation Unit, Hospital Clínic de Barcelona, ICHMO, Barcelona, Spain
[17] Unit of Hematology and Stem Cell Transplantation, Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy
[18] American University of Beirut Dept. of Medicine, Beirut, Lebanon
[19] Saint-Antoine Hospital, Sorbonne University, Paris, France
[20] Department of Haematology and EBMT Paris study office / CEREST-TC, Saint Antoine Hospital, INSERM UMR 938 and Université Pierre et Marie Curie, Paris, France

*DNMT3A* gene mutations are more frequent in cytogenetically normal acute myeloid leukemia (AML) and frequently associated with *NPM1* mutation and internal tandem duplication (ITD) of the *FLT3* gene. However, *DNMT3A* mutation is not included as a distinct prognostic group in the recent European Leukemia Net (ELN) 2022 genetic risk classification of AML. In the context of allogeneic hematopoietic cell transplantation (allo-HCT), the prognostic value of *DNMT3A* is still not well studied. We evaluated, through the European Society for Blood and Marrow Transplantation (EBMT) registry, the impact of *DNMT3A* mutation, according to the karyotype, and *NPM1* and *FLT3*-ITD mutation status, on post-transplant outcomes in AML patients receiving allo-HCT in first complete remission (CR1).

We identified a total of 1374 adult AML patients (51% female, median age 57 years; range 18-78 years) with ELN-2022 intermediate- or poor-risk cytogenetics and available *DNMT3A, FLT3ITD* and *NPM1* mutation status, who underwent their first allo-HCT in CR1 between 2013 and 2021. Of these, 631 (46%) patients had *DNMT3A* mutation. Patients with mutant *DNMT3A* were more likely to be female (57% versus 46%, $p<0.001$), to have normal cytogenetics (75% versus 54%, $p<0.001$), *FLT3*-ITD co-mutation (50% vs 23%, $p<0.001$), *NPM1* co-mutation (60% vs 21%, $p<0.001$), and to receive a myeloablative conditioning and *in vivo* T cell depletion. After a median follow-up of 2.3 years, the 2-year leukemia free survival (LFS) and overall

survival (OS) were 62% and 69%, respectively. The subsequent analysis was split according to baseline karyotype (normal or abnormal).

Among 870 patients with normal cytogenetics, 472 (54%) patients had *DNMT3A* mutation. The 2-year relapse incidence (RI), LFS and OS were 24%, 63% and 70% respectively, in patients with *DNMT3A* mutation compared to 18%, 69% and 74% in patients with *wild type DNMT3A*. Among these patients with normal karyotype, multivariable analyses (MVA) were done within the 4 groups of FLT3-ITD and NPM1 mutations. Within the group of 324 patients with both FLT3-ITD and NPM1 positives, 244 were triple-positive (75%), LFS and OS were not significantly different with and without *DNMT3A* mutation (2y LFS: 62% vs 63%, HR: 0.98, p=0.95; 2y OS: 70% vs 73%, HR: 1.17, p=0.58). Conversely, among 146 patients with *NPM1* mutation without *FLT3*-ITD, LFS was significantly lower for 91 patients with DNMT3A mutation (2y LFS: 68% vs 87%, HR: 2.70, p=0.02) but OS was not significantly different (2y OS: 79% vs 87%, HR: 2, p=0.13). On the other hand, among 318 with wild type *NPM1* and without *FLT3*-ITD, LFS and OS were not significantly different for 108 patients with DNMT3A mutation compared to 210 patients with wild type *DNMT3A* (2y LFS: 62% vs 67%, HR: 1, p=0.98; 2y OS: 65% vs 71%, HR: 1.02, p=0.94). Conversely, among 82 patients with *FLT3*-ITD and wild type *NPM1*, 2-year LFS and OS were 53% and 58% respectively, for 29 patients with *DNMT3A* mutation compared to 71% and 76% respectively, for 53 patients with wild type *DNMT3A*. The number of patients didn't allow to perform MVA in this group.

Finally, among 504 patients with abnormal cytogenetics, 159 (31%) patients had *DNMT3A* mutation. On MVA, *DNMT3A* mutation did not significantly affect LFS or OS. Poor-risk cytogenetics was associated with worse LFS, OS and increased RI. Older age negatively affected LFS and OS.

In conclusion, in AML patients allografted in CR1, the impact of *DNMT3A* mutation depends on the karyotype and co-occurring mutations. Our data suggest that *DNMT3A* mutation negatively affects post-transplant survival selectively in patients with normal karyotype and either *NPM1* mutation without *FLT3*-ITD, or patients with normal karyotype, *FLT3*-ITD and wild type *NPM1*. *DNMT3A* mutation shows no impact on post-transplant outcomes in other settings.

**Disclosures Huynh:** *Medac:* Other: Advisory board; *Astellas:* Other: Advisory board; *Pfizer:* Other: advisory board; *Jazz:* Other: travel fees, advisory board; *Servier:* Other: Advisory board; *Neovii:* Other: Advisory board; *Novartis:* Other: travel fees, advisory board. **Mayer:** *MSD:* Research Funding; *Novartis:* Research Funding. **Esteve:** *Jazz Pharmaceuticals:* Consultancy, Research Funding; *Abbvie:* Consultancy; *Gilead:* Consultancy; *Kronos Bio:* Research Funding; *Pfizer:* Research Funding; *Astellas:* Consultancy. **Ciceri:** *ExCellThera:* Other: Scientific Advisory Board . **Mohty:** *JAZZ PHARMACEUTICALS:* Honoraria, Research Funding.




| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DNMT3A-;NPM1-;FLT3ITD-: | 210 | 198 | 161 | 149 | 144 | 138 | 117 | 116 | 109 | 105 | 98 |
| DNMT3A-;NPM1-;FLT3ITD+: | 53 | 50 | 39 | 39 | 39 | 36 | 33 | 32 | 29 | 29 | 25 |
| DNMT3A-;NPM1+;FLT3ITD-: | 55 | 52 | 39 | 38 | 38 | 34 | 31 | 31 | 29 | 29 | 27 |
| DNMT3A-;NPM1+;FLT3ITD+: | 80 | 72 | 58 | 55 | 52 | 49 | 41 | 40 | 39 | 37 | 34 |
| DNMT3A+;NPM1-;FLT3ITD-: | 108 | 99 | 78 | 67 | 63 | 60 | 48 | 46 | 41 | 40 | 32 |
| DNMT3A+;NPM1-;FLT3ITD+: | 29 | 24 | 18 | 16 | 14 | 12 | 10 | 10 | 9 | 8 | 8 |
| DNMT3A+;NPM1+;FLT3ITD-: | 91 | 83 | 71 | 68 | 66 | 57 | 44 | 41 | 37 | 36 | 32 |
| DNMT3A+;NPM1+;FLT3ITD+: | 244 | 218 | 163 | 152 | 147 | 134 | 112 | 104 | 96 | 90 | 78 |

**Figure 1**

https://doi.org/10.1182/blood-2023-179531